We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares

Delisted

RVLP was delisted on the 20th of October, 2023.

41 hedge funds and large institutions have $28.7M invested in RVL Pharmaceuticals plc Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

14% more funds holding

Funds holding: 3641 (+5)

3% more capital invested

Capital invested by funds: $27.9M → $28.7M (+$794K)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
0.65%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
3
Reduced
10
Closed
2
Calls
$186K
Puts
Net Calls
+$186K
Net Calls Change
-$7K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1
Athyrium Capital Management
New York
$16.6M
RA
2
Rovida Advisors
Florida
$3.42M
ACH
3
ArrowMark Colorado Holdings
Colorado
$1.85M
ACM
4
AIGH Capital Management
Maryland
$1.43M -$655K -545,471 -30%
Morgan Stanley
5
Morgan Stanley
New York
$1.21M -$46.9K -39,075 -4%
Renaissance Technologies
6
Renaissance Technologies
New York
$795K -$21.4K -17,800 -2%
SM
7
Scoggin Management
New York
$570K +$600K +500,000 New
WVP
8
Worth Venture Partners
New Jersey
$368K -$160K -133,131 -29%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$350K
UOC
10
UBS O'Connor
Illinois
$315K +$332K +276,428 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$281K
BlackRock
12
BlackRock
New York
$243K +$13.1K +10,895 +5%
Millennium Management
13
Millennium Management
New York
$183K -$16.2K -13,536 -8%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$146K +$8.34K +6,947 +6%
MWM
15
Marietta Wealth Management
Georgia
$137K
TAM
16
Titleist Asset Management
Texas
$120K +$126K +105,003 New
State Street
17
State Street
Massachusetts
$89.7K
IA
18
Insight Advisors
Pennsylvania
$86.2K +$45.4K +37,823 +100%
Northern Trust
19
Northern Trust
Illinois
$83.1K
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$82.9K -$28.2K -23,487 -24%
Citadel Advisors
21
Citadel Advisors
Florida
$47.4K -$6.72K -5,604 -12%
BCM
22
Bridgeway Capital Management
Texas
$35.9K
RJFSA
23
Raymond James Financial Services Advisors
Florida
$33.7K
AWS
24
Atria Wealth Solutions
New York
$26.2K
LPL Financial
25
LPL Financial
California
$24.2K +$25.5K +21,210 New

RVLP Hedge Fund Activity: Q1 2023 in Review

41 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2023, worth a combined $28.7M — up 2.8% from $27.9M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new RVLP positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 10 trimmed.

The largest buyer was Scoggin Management, opening a new position worth an estimated $600K. The largest seller was AIGH Capital Management, cutting an estimated $655K.

  • 41 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2023, up from 36 in Q4 2022.
  • Funds reported $28.7M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2023, up 2.8% quarter-over-quarter.
  • 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2023 and 2 closed out, a net change of +6 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2023 was Scoggin Management, an estimated $600K added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2023 was AIGH Capital Management, an estimated $655K sold.

Based on aggregated 13F filings for Q1 2023.